Epeleuton
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT02673593)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CC/C=C\C[C@H](O)/C=C/C=C\C/C=C\C/C=C\CCCC(=O)OCC- Mol. weight
- 346.51 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095178 ↗
Also known as
- ds102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05861453 | Phase 2 | Nov 30, 2023 | Afimmune |
| NCT04365400 | Phase 2 | Sep 1, 2020 | Afimmune |
| NCT03452540 | Phase 2 | Jun 30, 2018 | Afimmune |
| NCT03414541 | Phase 2 | Sep 24, 2017 | Afimmune |
| NCT02941549 | Phase 2 | Oct 1, 2016 | Afimmune, University of Birmingham |
| NCT02673593 | Phase 1 | Jul 1, 2015 | DS Biopharma |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Afimmune | For profit | 5 | 5 | 1 | 2016 |
| DS Biopharma | For profit | 1 | 1 | 1 | 2015 |
| University of Birmingham | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1